Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Igor Golovniov/SOPA Images/LightRocket via Getty Images

Pharmaceutical company Eli Lilly made its first offer to buy Loxo Oncology on Dec. 20, 2018, and it was eager to close the deal before the J.P. Morgan Healthcare Conference last week, according to new regulatory documents filed by Loxo.

Between the lines: Acquisitions usually take several months of negotiations, not 2 weeks, but both sides in this $8 billion deal moved extraordinarily quickly in part to make a big splash at the health care industry's signature event.

Details: Eli Lilly and Loxo had been in touch since April 2018, but acquisition talks did not begin until last month.

  • Loxo has one FDA-approved drug on the market, but Eli Lilly appeared to be most interested in LOXO-292 — a cancer drug that had "positive interim data" in early clinical trials and received "breakthrough" status from the FDA in September.
  • Loxo did not pursue any other offers, and Eli Lilly only revised its offer once — from the initial $230 per share to the final $235 per share. Loxo's board said Eli Lilly's deal outweighed "the risks of outreach to third parties," according to the filing.
  • Josh Bilenker — an oncologist who used to work at the FDA, is Loxo's CEO and is an operating partner at the private equity firm Aisling Capital, which owns a large chunk of Loxo — will make $45 million from the shares he owns once the deal closes, according to the documents. Bilenker will make another $241 million from the deal based on his vested and unvested stock options.
  • Loxo expects revenue of all of its cancer medicines will peak in 2031 at $2 billion with a 43% profit margin, assuming FDA approvals.

Go deeper

18 mins ago - Politics & Policy

Scoop: Hundreds of Biden staffers receive COVID vaccine

Screenshots of an email inviting White House staff to receive the COVID-19 vaccine, obtained by Alayna Treene/Axios

A week into the job, President Biden's White House medical team has administered the coronavirus vaccine to several hundred staffers — and aims to vaccinate all in-person staff over the next few weeks, officials tell Axios.

Why it matters: The new administration is ramping up steps to protect President Biden and all staff working inside the White House complex. The administration is also requiring daily employee COVID tests and N95 masks at all times.

Dan Primack, author of Pro Rata
1 hour ago - Economy & Business

The Leon Black clock strikes midnight

Illustration: Sarah Grillo/Axios

Leon Black is "retiring" as CEO of Apollo Global Management, the alternative investment giant he has led since co-founding it in 1990. But he is not making a full break, as Black will remain chair of Apollo's board of directors.

Why it matters: This is the culmination of 18 months of head-in-the-sand obfuscation of Black's dealings with Jeffrey Epstein.

Reddit traders look to pummel Wall Street's old guard

Illustration: Sarah Grillo/Axios

Reddit traders are taking on Wall Street pros at their own game with this basic mantra: Stocks will always go up.

Why it matters: Their trades — egged on in Reddit threads — have played a role in historic market activity in recent days.